RxDoctor Payments Data

Emiliano Baquir

Psychiatric/Mental Health · Valencia, CANPI 1861951352

Payments from drug & device makers

$2,838in general payments, 2019–2025

Across 117 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$732
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$392
  • Tris Pharma Inc$250
  • Teva Pharmaceuticals USA, Inc.$203
  • Takeda Pharmaceuticals U.S.A., Inc.$201
  • Otsuka America Pharmaceutical, Inc.$167
  • plus $893 from 11 others

What the payments were for

  • Food & beverage$2,74397%
  • Education$963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,838 in reported general payments places this provider in the 80th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$69,040
Medicare patients
124
Services billed
931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$23,794
RexultiBrexpiprazole11$19,822
TrintellixVortioxetine Hydrobromide36$17,262
Lurasidone Hcl15$10,893
VyvanseLisdexamfetamine Dimesylate12$5,282
XanaxAlprazolam11$4,382
Aripiprazole45$3,814
Quetiapine Fumarate40$1,687
Atomoxetine Hcl25$1,080
Buspirone Hcl94$942
Oxcarbazepine20$706
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$684
Trazodone Hcl42$659
Clonazepam60$654
Lorazepam96$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$732$23,79417 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$201$22,54448 claims
Otsuka America Pharmaceutical, Inc.Rexulti$167$19,82211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →